CTOs on the Move

Home Advantage

www.home-adv.com

 
Home Advantage is a Herndon, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.home-adv.com
  • 13800 Coppermine Rd Ste 300
    Herndon, VA USA 20171
  • Phone: 800.297.2180

Executives

Name Title Contact Details

Similar Companies

Loyal

Loyal is part of Cellular Longevity, a company working to develop the first drugs explicitly intended to extend healthspan and lifespan — first in dogs, and then in humans, too. By quantifying and controlling the mechanisms of aging, we hope to delay the onset and reduce the severity of age-related diseases, which means more, healthier years for both species. At Loyal, our first products to market are focused on longevity and healthspan in dogs. Join us in our mission to help dogs everywhere.

New Century Hospice

New Century Hospice is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Dermira

Dermira is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Turn Biotechnologies

Turn Biotechnologies develops mRNA medicines that induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue. We are focused on reprogramming the epigenome – a network of chemical compounds and proteins that control cell functions by influencing which genes are active – to restore capabilities that are often lost with age.

CytomX

CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company`s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, MD Anderson Cancer Center and ImmunoGen, Inc.